share_log

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 First Quarter Results

SEC announcement ·  Jan 4 13:00
Summary by Futu AI
On January 4, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the first fiscal quarter ending November 30, 2023. The company announced a net loss of $67 million, a significant improvement from the $3.7 billion net loss in the previous year's quarter. This improvement was primarily due to the absence of a $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter. Despite the net loss, WBA saw a 10% increase in sales year-over-year, reaching $36.7 billion. The adjusted earnings per share (EPS) decreased by 43.1% to $0.66, influenced by challenging retail market trends in the U.S. and a higher tax rate. WBA also declared a 48% reduction in its quarterly dividend payment to $0.25 per share. The company...Show More
On January 4, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the first fiscal quarter ending November 30, 2023. The company announced a net loss of $67 million, a significant improvement from the $3.7 billion net loss in the previous year's quarter. This improvement was primarily due to the absence of a $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter. Despite the net loss, WBA saw a 10% increase in sales year-over-year, reaching $36.7 billion. The adjusted earnings per share (EPS) decreased by 43.1% to $0.66, influenced by challenging retail market trends in the U.S. and a higher tax rate. WBA also declared a 48% reduction in its quarterly dividend payment to $0.25 per share. The company maintained its fiscal 2024 adjusted EPS guidance of $3.20 to $3.50, expecting underlying earnings growth to be offset by various factors including a higher tax rate and lower COVID-19 contributions. The U.S. Healthcare segment reported a sales increase to $1.9 billion, with VillageMD and Shields driving growth. The U.S. Retail Pharmacy segment saw a 6.4% increase in sales, while the International segment's sales rose by 12.4%. WBA's CEO Tim Wentworth emphasized the company's focus on strategic options to drive long-term shareholder value, cost management, and cash flow improvement.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.